[go: up one dir, main page]

AU2017300579A1 - Therapeutic agents for neurological and psychiatric disorders - Google Patents

Therapeutic agents for neurological and psychiatric disorders

Info

Publication number
AU2017300579A1
AU2017300579A1 AU2017300579A AU2017300579A AU2017300579A1 AU 2017300579 A1 AU2017300579 A1 AU 2017300579A1 AU 2017300579 A AU2017300579 A AU 2017300579A AU 2017300579 A AU2017300579 A AU 2017300579A AU 2017300579 A1 AU2017300579 A1 AU 2017300579A1
Authority
AU
Australia
Prior art keywords
neurological
therapeutic agents
psychiatric disorders
psychiatric
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2017300579A
Other versions
AU2017300579B2 (en
Inventor
Bart De Strooper
Joris DE WIT
Heather RICE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB filed Critical Katholieke Universiteit Leuven
Priority claimed from PCT/EP2017/067859 external-priority patent/WO2018015296A1/en
Publication of AU2017300579A1 publication Critical patent/AU2017300579A1/en
Application granted granted Critical
Publication of AU2017300579B2 publication Critical patent/AU2017300579B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2017300579A 2016-07-20 2017-07-14 Therapeutic agents for neurological and psychiatric disorders Active AU2017300579B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16180433 2016-07-20
EP16180433.1 2016-07-20
PCT/EP2017/067859 WO2018015296A1 (en) 2016-07-20 2017-07-14 Therapeutic agents for neurological and psychiatric disorders

Publications (2)

Publication Number Publication Date
AU2017300579A1 true AU2017300579A1 (en) 2019-02-21
AU2017300579B2 AU2017300579B2 (en) 2023-02-09

Family

ID=56511366

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017300579A Active AU2017300579B2 (en) 2016-07-20 2017-07-14 Therapeutic agents for neurological and psychiatric disorders

Country Status (5)

Country Link
US (1) US10829528B2 (en)
EP (1) EP3488242B1 (en)
AU (1) AU2017300579B2 (en)
CA (1) CA3031401A1 (en)
WO (1) WO2018015296A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023017190A1 (en) 2021-08-13 2023-02-16 Vib Vzw NOVEL MODULATORS OF GABABR1a
EP4626908A1 (en) * 2022-11-28 2025-10-08 University of Copenhagen Peptides capable of inhibiting protein-protein interactions at gaba-b1a subunit and uses thereof
WO2025049947A1 (en) * 2023-09-01 2025-03-06 University Of Southern California A modular tool for transsynaptic labeling based antibody mimetics

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2308102A1 (en) * 1997-10-27 1999-05-06 Astrazeneca Aktiebolag New nucleotide sequences
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003072041A2 (en) * 2002-02-27 2003-09-04 Merck & Co., Inc. Assays to monitor amyloid precursor protein processing
FR2904113A1 (en) * 2006-07-21 2008-01-25 Exonhit Therapeutics S A Sa METHODS AND TOOLS FOR THERAPY OF NEURODEGENERATIVE PATHOLOGIES
US8247385B2 (en) * 2007-02-06 2012-08-21 Tai June Yoo Treatment and prevention of neurodegenerative diseases using gene therapy
WO2009152463A2 (en) * 2008-06-12 2009-12-17 Genentech, Inc. Method for screening for compounds that inhibit neurodegeneration
CN109414482A (en) * 2016-05-12 2019-03-01 俄亥俄州创新基金会 Peptides and methods for treating neurodegenerative diseases

Similar Documents

Publication Publication Date Title
ZA201900519B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
IL267082A (en) Systems and methods for treating neurological disorders
IL267818A (en) Methods for the treatment of neurological disorders
PT3416631T (en) Therapeutic agents for neurodegenerative diseases
IL273705A (en) Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
EP3119911A4 (en) Methods for treating neurological disorders
EP3310358A4 (en) Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
EP3634986A4 (en) Gene therapy for ocular disorders
IL273929A (en) Therapeutic agents for neurodegenerative diseases
IL268946A (en) Gene therapy for ocular disorders
AU2017300579A1 (en) Therapeutic agents for neurological and psychiatric disorders
PT3458067T (en) Treatment of neurological disorders
EP3551281A4 (en) Monitoring and treatment system for neurological disorders
IL275613A (en) Gene therapy for eosinohilic disorders
EP3507277B8 (en) Hydroxynorketamine derivatives for the treatment of disorders
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
HK40119093A (en) Methods for the treatment of cysteamine sensitive disorders
HK40015417A (en) Methods for the treatment of neurological disorders
HK40038648A (en) Combination product for the treatment of neurological and/or psychiatric disorders
HK40008377A (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
HK40007595A (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
HK40007595B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
HK40025173A (en) Therapeutic agents for neurodegenerative diseases
HK40019969A (en) Methods for treating neurodegenerative disorders
HK40029092A (en) Gene therapy for ocular disorders